https://scholars.lib.ntu.edu.tw/handle/123456789/195595
標題: | Boostrix (Tm): A Reduced-Dose Acellular Pertussis Vaccine for Use in Adolescents and Adults | 作者: | LI, WEN-CHEN WU, TSUNG-ZU HUANG, YHU-CHERING HUANG, LI-MIN HUANG, LI- MIN |
關鍵字: | Boostrix (TM);Bordetella pertussis;seroepidemiology;Tdap | 公開日期: | 2009 | 卷: | VACCINES | 期: | n.10 | 起(迄)頁: | 1317-1327 | 來源出版物: | EXPERT REVIEW OF | 摘要: | Pertussis remains a serious problem in many countries. Even in countries with high vaccine coverage and a long vaccination history, pertussis outbreaks occur periodically. Rather than being a disease of young children, pertussis has shifted to affect adolescents and adults. increased pertussis burden in adolescents and adults is the major source of severe infection for young infants. An effective vaccine is needed to control the spread of pertussis beyond preschool children. Boostrix (TM) is a reduced-dose acellular pertussis vaccine with diphtheria and tetanus toxoids, and is designed for use in adolescents and adults. Current evidence suggests that Boostrix is immunogenic and well tolerated. The pertussis component of Boostrix has been shown to be efficacious in a large-scale Phase III trial. More than 50 countries have given permit to the use of Boostrix, and many of them formally recommend the use of Boostrix in adolescents and adults. Designed as a vaccine for adolescence and adults, Boostrix has a long way to go to achieve large-scale use in those target groups. Nevertheless, we expect that the advent of Boostrix will lead to a much better control of pertussis in the general population. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/186775 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。